Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, gives a brief overview of bispecific antibodies emerging for the treatment of multiple myeloma, highlighting the main differences between BCMA-targeting and GPRC5D-targeting agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.